Clinical trial · Observational
Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
Study on Precision Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
NCT06939400CI-TRIAL-00088766not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma Multiforme (GBM) | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GBM patients recevied traditional treatment options | Procedure | — | UNRESOLVED |
| Photodynamic therapy (PDT) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Control
- description
- GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)
- interventionNames
- Procedure: GBM patients recevied traditional treatment options
- label
- Treatment
- description
- GBM patients recevied surgical combination photodynamic therapy
- interventionNames
- Procedure: Photodynamic therapy (PDT)
Primary outcomes (1)
- measure
- Number of Participants with Treatment of Surgical combination Photodyanmic therapy
- timeFrame
- From June 2025 to June 2027
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.
Exclusion Criteria:
* Photosensitizer allergy.
* Severe coagulation disorder.
* Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage.
* Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties.
Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.References
Publications (0)
Data not yet available
No reference posted for this study.